Merck Splits Human-Health Business, Creates Cancer Unit to Offset Keytruda Patent Loss
Merck will reorganize its human-health business into separate units, establishing a dedicated cancer division to mitigate expected sales pressure from Keytruda’s patent loss. The new operating structure aims to streamline portfolio execution and accelerate oncology launches to offset looming revenue declines.
1. Business Structure Evolution
On February 23, Merck announced it will divide its human-health segment into two distinct operating units, including a standalone cancer division. This reorganization centralizes oncology R&D and commercial teams to sharpen focus on cancer therapies and improve operational alignment.
2. Patent Exclusivity Headwinds
The new cancer unit is designed to counter anticipated revenue headwinds from Keytruda’s upcoming patent loss. As Merck’s top-selling immunotherapy, Keytruda’s loss of exclusivity threatens to erode billions in annual sales.
3. Strategic Outcomes
By realigning under a focused oncology division, Merck aims to streamline portfolio execution and accelerate late-stage therapy launches. This structure is intended to bolster development efficiency and support upcoming product rollouts to compensate for declining Keytruda revenues.